Technical corrections only. The changes between v3 and v4 reflect the bill's procedural status update from "Engrossed in House" to "Placed on Calendar Senate," including updated header and footer information. There are no substantive policy changes to the bill's text.
Stem Cell Therapeutic and Research Reauthorization Act of 2025
- Sponsor
- Rep. Smith, Christopher H. [R-NJ-4]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Jul 21, 2026
Bottom line
The bill ensures continued federal support for life-saving stem cell transplantation programs and modernizes the management of the national cord blood supply to align with current scientific understanding and maximize clinical utility.
What it actually does
This bill reauthorizes the Stem Cell Therapeutic and Research Act of 2005, specifically extending funding for the C.W. Bill Young Cell Transplantation Program and modifying provisions related to the National Cord Blood Inventory. It increases authorized appropriations for the transplantation program and grants the Secretary of Health and Human Services greater flexibility in managing the cord blood inventory based on scientific and clinical considerations.
Proponents argue
Supporters argue that this reauthorization is vital for maintaining and advancing access to life-saving stem cell transplants for patients with critical medical conditions. They emphasize that updating the cord blood inventory management to reflect the best available science will lead to more efficient resource allocation, improved genetic diversity, and a more clinically useful supply of cord blood units.
Opponents contend
Direct opposition to the reauthorization of this program is not typically raised due to its established public health benefits. Potential concerns, if any, might focus on the specific funding levels in the context of broader budget priorities, or questions about the transparency and accountability of the Secretary's increased discretion in managing the cord blood inventory, though such arguments are not explicitly present in public discourse regarding this type of reauthorization.
The bill is concise and clearly written, allowing for quick and straightforward comprehension by an informed reader.
Section 2
Reauthorization of C.W. Bill Young Cell Transplantation Program Funding
This section extends the authorization of appropriations for the C.W. Bill Young Cell Transplantation Program. It increases the annual authorized funding from $31,009,000 to $33,009,000 for each of fiscal years 2027 through 2031. This program supports activities related to bone marrow and cord blood transplantation, including maintaining a national registry of donors.
Supporters argue
Supporters argue that this reauthorization is crucial for sustaining the C.W. Bill Young Cell Transplantation Program, which is instrumental in facilitating life-saving transplants. The increased funding reflects rising operational costs and the ongoing demand for these critical medical services, ensuring the program's continued effectiveness and reach.
Critics contend
Direct opposition to reauthorizing this program is rare due to its widely recognized life-saving mission. Any potential concerns, if raised, would likely focus on the specific funding increase in the context of broader federal budget constraints, rather than challenging the program's fundamental purpose.
Tradeoffs
The primary tension involves balancing the critical need for sustained funding for life-saving medical treatments with overall federal budget priorities. The modest increase in authorized funding reflects a decision to prioritize the program's needs to maintain its vital services.
Section 3(a), (d), (e)
Modernization of Cord Blood Inventory Management
This provision removes the specific numerical target of "at least 150,000 new units of high-quality cord blood" for the National Cord Blood Inventory. Instead, it directs the Secretary of Health and Human Services to determine a "sufficient supply" and introduces new authority for the Secretary to manage the inventory's size and composition. This management will prioritize clinical utility, genetic diversity, and efficient resource use, allowing for decisions on collection, retention, or disposition based on scientific and clinical evidence. It also formally defines a "high quality cord blood unit."
Section 3(b)(2)
Authority to Transfer Cord Blood Units from Non-Compliant Banks
This amendment grants the Secretary of Health and Human Services the authority to transfer cord blood units from a bank that is no longer operational, fails to meet specified requirements, or cannot distribute units, to another qualified cord blood bank or approved entity. This measure is intended to ensure the continued availability of high-quality cord blood units for patients.
This provision amends Section 2(c)(2) of the original Stem Cell Therapeutic and Research Act of 2005 by striking the phrase "in perpetuity or" from the language regarding the storage of cord blood units.
Section 3(b)(1)
Why it matters:This is standard legislative practice for making precise textual changes to existing law, not necessarily an attempt to be evasive. It aligns with the broader intent of modernizing inventory management.
Case for: Supporters would argue that removing the 'in perpetuity' requirement aligns with the new inventory management flexibility introduced in Section 3(e). It allows for the disposition of units that are no longer clinically useful or meet current quality standards, preventing indefinite storage of unusable units and promoting efficient resource allocation based on the best available science.
Case against: Critics might express concern that removing 'in perpetuity' could, in extreme scenarios, be interpreted as allowing for the premature disposal of units that might gain utility with future, unforeseen scientific advancements. However, the bill's emphasis on 'best science' and 'clinical utility' is intended to mitigate such risks.
Estimated impact: This change, when combined with the new inventory management section, allows for more dynamic and potentially more efficient management of the entire cord blood inventory, impacting long-term storage costs and the composition of available units.